Regulatory Blessings Helping China CAR-Ts March Closer To Global Cancer Patients?
Cost Advantages May Also Come To Fore
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.
